Managing Bipolar Disorder: The Pharmacist’s Role in Delivering Quality Care
1.0 Credits / Psychiatry
The Value of Early Intervention With Long-Acting Injectable Antipsychotics to Improve Adherence and Treatment of Schizophrenia
1.5 Credits / Neurology, Psychiatry
Continuing the Conversation: Advancements in Integrated Continuous Glucose Monitoring Devices and Best Practices to Customize Care (Technician Credit)
2 Credits / Endocrinology
Continuing the Conversation: Advancements in Integrated Continuous Glucose Monitoring Devices and Best Practices to Customize Care
2 Credits / Endocrinology
Promoting Adherence in Early-Stage HR+/HER2- Breast Cancer: The Value of Oncology Pharmacists in Preventing Premature Treatment Discontinuation
1.25 Credit(s) / Oncology; Women’s Health
A Pharmacologic Overview of Antibody-Drug Conjugates
2.0 Credits / Oncology
Investigating Novel Strategies for the Treatment of Metastatic Small Cell Lung Cancer After Frontline Treatment Failure
1.0 Credit / Oncology
Clinical Updates and Strategies for Optimizing Use of Bispecific Antibodies in Hematologic Malignancies
1.0 Credit / Oncology
Long-term Data Show Efficacy of Amivantamab-vmjw Combination for Patients With Mutated Advanced Non-Small Cell Lung CancerJune 5th 2023
In data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, amivantamab-vmjw plus lazertinib demonstrated promise as a first-line treatment for patients with advanced EGFR-mutated non-small cell lung cancer.
Overall Survival of Patients With Metastatic NSCLC Sustained Up to 4 Years With Opdivo, Yervoy CombinationJune 5th 2023
Nivolumab plus ipilimumab combination improved overall survival, with 21% of individuals with metastatic non–small cell lung cancer treated with the combination and 2 cycles of chemotherapy alive compared to 16% with chemotherapy alone.
Durvalumab, Olaparib Combination Improves Progression-Free Survival in Patients With Advanced Ovarian CancerJune 5th 2023
Positive findings in patients with advanced high-grade epithelial ovarian cancer were presented during an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting.
FDA Approves First Intravenous Iron Replacement Therapy for Adults With Heart Failure, Iron DeficiencyJune 5th 2023
Treatment with Injectafer significantly improved exercise capacity compared to placebo in a randomized clinical trial in adult patients with heart failure.
Clinical Overview: Steps to Implementation of Rebyota for Recurrent C difficile InfectionJune 5th 2023
Rebyota is a live biotherapeutic product that is unfamiliar to many pharmacists and other health care providers with different steps in the eventual administration process.
Overall Survival Results Reinforce Osimertinib is Now Standard of Care for EGFRm Stage IB–IIIA NSCLCJune 5th 2023
Updated overall survival and safety profile data from the global phase 3 ADAURA trial provide practice-changing findings with adjuvant osimertinib (Tagrisso; AstraZeneca) in patients with resected EGFR-mutated stage IB–IIIA NSCLC.
With Perioperative Pembrolizumab, Event-Free Survival for Early-Stage Lung Cancer Was 62% at the Interim Analysis of Phase 3 KEYNOTE-671June 4th 2023
Expert said these striking results, coupled with benefits across all subgroups and potential overall survival, suggests efficacy for adults with early-stage non-small cell lung cancer.
Addition of Pembrolizumab to Chemotherapy Can Significantly Improve Survival Outcomes in Patients with Cervical CancerJune 4th 2023
Expert discusses the long wait for an effective therapeutic option for persistent, recurrent, or metastatic cervical cancer and the potential widespread benefits of antibody drug conjugates like pembrolizumab.
New Manufacturing Process Could Improve CAR T Cell Efficacy Against Aggressive Form of LeukemiaJune 3rd 2023
Expert said that manufacturing the T cells with a tyrosine kinase inhibitor may allow more patients to get allogeneic stem cell transplant, the current best means of long-term cure.
Analysis of Gut Microbiome Did Not Show Significant Differences Relating to Immune Checkpoint Inhibition ResistanceJune 3rd 2023
Fecal microbiota transplant from responders to non-responders was able to rescue immune checkpoint inhibition use in patients with melanoma, with 40% of patients showing clinical benefit.
Larotrectinib Subgroup Analyses Demonstrate Long-Term Efficacy, Safety Profile in NTRK Gene Fusion CancerJune 2nd 2023
Findings presented at the American Society of Clinical Oncology (ASCO) 2023 meeting show the long-term efficacy and safety profile of larotrectinib (Vitrakvi; Bayer) in solid tumors with NTRK gene fusion.
Clinical Overview: Dapagliflozin for Patients with Heart Failure, Reduced Ejection Fraction and Preserved Ejection FractionJune 2nd 2023
Management of heart failure focuses on avoiding reversible precipitants and optimizing guideline-directed therapy to lower mortality and hospitalizations.
Ribociclib Lowers Risk of Disease Recurrence by 25% for Early Breast CancerJune 2nd 2023
Ribociclib (Kisqali) demonstrated a 26% risk reduction in distant disease-free survival and a 28% risk reduction in recurrence-free survival in patients with HR+/HER2- early breast cancer.
Five-Year Data Show Superiority of Upadacitinib to Adalimumab Treating Rheumatoid ArthritisJune 2nd 2023
Upadacitinib 15 mg once daily had a better clinical response compared to adalimumab 40 mg every other week at 12 weeks in 3-year follow-up data among patients with rheumatoid arthritis.